Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

City Of Hope's Joseph Alvarnas On CAR-T Real-World Use, Reimbursement

Executive Summary

City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.

Advertisement

Related Content

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests
Value-Based Payment Experiments For Drugs To Be Key Focus For CMMI, Director Says
Minimal Residual Disease 'Coming Soon' As An Approval Endpoint, Celgene Says
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124305

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel